Saturday, July 5, 2025 7/5/2025

Development of a dengue exposure monitor

Award Number: R43AI155067
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2020
PERIOD OF PERFORMANCE END DATE: 10/31/2021

Group Awards By:

View Award Description

Development of a dengue exposure monitor - PROJECT SUMMARY Approximately 40% of the world’s population, 2.5 billion people, are at risk of contracting dengue fever. The disease is endemic to tropical regions in Central and South America, Africa, and Asia. Outbreaks have also occurred in the southern portions of the United States, including Florida and Texas, as well as the Hawiian islands.The FDA has approved a single vaccine against dengue. Both safety and efficacy of the vaccine depend on whether or not the recipient has been previously exposed to the dengue virus. The potential for severe dengue disease in seronegative individuals receiving the vaccination (especially for children ages 2-4) underscores the need for a field-deployable device to determine if individuals have previously been infected by the dengue virus. There is a concern that a universal vaccination program could have deleterious effects on populations living in regions where infection is the norm. Thus, a rapid, economical, point-of-care (POC) assay to determine if an individual has been exposed to the virus will be significant. Data from this assay will assist the medical community in establishing an anti-dengue vaccination protocol. Lynntech proposes to develop a portable, highly sensitive, and highly specifc diagnostic that is capable of detecting anti-dengue antibodies in human samples. Anti-dengue antibodies will be specifically recognized and captured by high affinity ligands, resulting in the generation of an electrochemical signal reflecting pre- exposure to the dengue virus. The Lynntech system will offer a straightforward, POC means to assess the serological profile of individuals with respect to their previous exposure to the dengue virus. The global need for such an assay bolsters market potential for the Lynntech product.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $755 )
2023	2020	LYNNTECH INC.	2501 EARL RUDDER FWY S	COLLEGE STATION	TX	77845	BRAZOS	USA	Allergy and Infectious Diseases Research	000	1	11/23/2022	NEW	$755
														Subtotal = $755

Issue Date FY: 2022 ( Subtotal = -$4,331 )
2022	2020	LYNNTECH INC	2501 EARL RUDDER FWY S	COLLEGE STATION	TX	77845	BRAZOS	USA	Allergy and Infectious Diseases Research	000	1	5/27/2022	NEW	-$4,331
														Subtotal = -$4,331

Issue Date FY: 2020 ( Subtotal = $244,402 )
2020	2020	LYNNTECH INC.	2501 EARL RUDDER FREEWAY S	COLLEGE STATION	TX	77845	BRAZOS	USA	Allergy and Infectious Diseases Research	001	1	8/18/2020	NEW	$20,170
2020	2020	LYNNTECH INC.	2501 EARL RUDDER FREEWAY S	COLLEGE STATION	TX	77845	BRAZOS	USA	Allergy and Infectious Diseases Research	000	1	7/31/2020	NEW	$224,232
														Subtotal = $244,402

Grand Total All Awards = $240,826

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of a dengue exposure monitor

Award Number: R43AI155067

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2020

PERIOD OF PERFORMANCE END DATE: 10/31/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer